Insights That Move the GPCR Field Forward

Bryan Roth joins the Dr. GPCR community live this week to examine what standard models don't account for — what happens when GPCR selectivity is encoded at the receptor–transducer interface rather than the receptor alone. This is one of 12+ live Masterclasses planned for 2026, all included in Premium. Also this week: Terry Hébert previews his April 16 session on iPSC-derived models, and a new podcast episode with Joseph Kim on GPCR structural biology and drug discovery.

Boston, MA and Irvine, CA — [March 18, 2026]  — Dr. GPCR, a nonprofit organization serving the global G protein-coupled receptor (GPCR) research community through education, curated scientific content, and community engagement, today announced a strategic media partnership with GeneTex, a multinational antibody manufacturer with long-standing expertise in reagent development and validation. Anti-GPCR antibody specificity has been a persistent challenge in the field — one with

Dr. GPCR and Eurofins DiscoverX announce a strategic partnership to accelerate GPCR drug discovery by expanding access to validated, industry-standard cell-based assay platforms supporting pharmacological characterization, screening, and regulatory-compliant development.

The difference between orthosteric vs. allosteric mechanisms isn’t just academic — an orthosteric antagonist can hijack receptor physiology, while an allosteric modulator works with the system. That choice determines whether you risk over- or under-dosing, miss safety windows, or miss therapeutic breakthroughs.